We investigated the influence on mitochondrial functions in carnitine deficiency caused by short-term treatment of cefterampivoxil (CFTM-PI) which is one of pivaloyloxymethyl-esterified antibiotics in adult volunteers and diseased children. Administration of CFTM-PI caused hypocarnitinemia in all cases, and we observed a significant elevation of blood ammonia levels compared with those after its withdrawal in diseased children. A significant negative correlation was found between the levels of serum free carnitine and blood ammonia, and a positive correlation was observed between serum carnitine and blood glutamine levels in all adult samples and samples during administration in diseased children. Our data suggest that these antibiotic medications affect the mitochondrial function even in a short-term treatment and that L-carnitine supplementation would be necessary for patients treated with CFTM-PI. carnitine deficiency; pivalic acid; hyperammonemia Carnitine, a cofactor for mitochondrial /l-oxidation of long-chain fatty acids, is essential for energy production and enhances the excretion of accumulated acyl-CoA to regulate the intramitochondrial CoA/acyl-CoA ratio. The systemic carnitine deficiency noted in various disorders can cause hypoketotic hypoglycemia, cardiomyopathy and Reye-like syndrome because functions of carnitine are insufficient.
otics is metabolized to produce pharmacological active site, formaldehyde and pivalic acid in the intestine. In humans, most pivalic acid binds tightly to carnitine and is excreted as pivaloylcarnitine into the urine, resulting in a carnitine deficiency (Melegh et al. 1987 ; Holme et al. 1989 ). Long-term administration of these antibiotics induces skeletal muscle myopathy (Rose et al. 1992 ; Diep et al. 1993 ) and excretion of dicarboxylic acid with limited ketone body formation during prolonged fasting (Diep et al. 1993 ).
However, little is known about the adverse reactions of carnitine shortage occurring in short-term administration of pivaloyloxymethyl-esterified antibiotics. In this study, we investigated the influence of cefteram-pivoxil (CFTM-PI, Toyama Chemical Co., Ltd., Tokyo), particularly on mitochondrial functions for adult volunteers and diseased children after both had been treated with this agent.
MATERIALS AND METHODS

Adult volunteers
Eight healthy Japanese male volunteers participated, whose age ranged from 21 to 27 years (mean ±S.D.: 23.3+2.4 years) and body weight ranged from 57.0 to 71.5 kg (62.2+5.5 kg). We obtained informed consent for the purpose of this study. Six subjects were given CFTM-PI (200 mg orally three times a day after meals is the normal therapeutic dose for adults) for seven days and the others selected at random were given a placebo. Blood samples after an overnight fast were collected daily from one day before the load (day 0) to day 8, then again on day 10 and day 13. Twenty-four-hour urine samples were collected daily from day 0 to day 10. Clinical observations (subjective and objective symptoms) were performed from day -1 to day 10 and day 13.
We measured serum and urine free carnitine, urine pivaloyl-carnitine, blood ammonia, lactate, pyruvate, serum pivalic acid, ketone bodies and plasma amino acids in those samples. Free carnitine was analyzed using L-carnitine dehydrogenase (Takahashi et al. 1994 ). Urine acyl-carnitine profile was analyzed by carboxylic acid analyzer (Kidouchi et al. 1987 ). Serum pivalic acid was quantitated by gas chromatography/mass spectrometry (Saikawa et al. 1986 ). Blood sample for ammonia was mixed with deproteinizing reagent solution immediately after venipuncture and measured by berthelot-indophenol method (Wako ammonia test, Wako Pure Chemical Ind., Ltd., Osaka). Plasma amino acids were analyzed by HPLC (Deyl et al. 1986 ).
Diseased children
Thirteen males and 4 females aged 23 months to 14 years (6.5+3.9 years) were given CFTM-PI for treatment or prophylactic use in upper respiratory infection, anaphylactoid purpura or surgical operation. The dosage was from 8.5 to 16.8 mg/kg/day (13.5 + 2.7 mg/kg/day: normal therapeutic dose for children) and the period of medication was from 3 to 14 days (6.2 ± 3.1 days). Blood samples following an overnight fast were obtained before , during and/or after the treatment. In seven patients of them, serial blood samples were collected before , during and after the therapy (5 males and 2 females aged 4 to 13 years; 8.4 + 3.1 years). The samples during administration were obtained from 2 to 12 days' treatment (4.5±2.8 days), and the samples after administration were from 1 to 4 days (3.0±1.2 days) after drug withdrawal.
We measured concentrations of blood ammonia, lactate, pyruvate, plasma amino acids and serum free carnitine in Fig. 1 
RESULTS
Adult volunteers
No pathological signs or symptoms were observed in any volunteers throughout this study. The concentration of serum free carnitine began to decrease at 2 days after CFTM-PI administration, as shown in Fig, 1A . The decrease was progressive, and the minimum mean level reached at day 7 was 18.7+4.4 nmol/ml (volunteers taking placebo at day 7: 50.8 + 4.5 nmol/ml ), which fully recovered to the pre-treatment level in 3 days after drug withdrawal and ordinary diet. Urinary concentrations of free carnitine changed mostly like those of serum free carnitine (Fig. 1B) . Fig. 2 showed the urinary acylcarnitine profile in a morning urine sample of a volunteer during administration. A large amount of pivaloylcarnitine was detected without other acylcarnitines. The urinary excretion of pivaloylcarnitine reached the plateau level on day 2. It disappeared immediately after discontinuing CFTM-PI administration (Fig. 1C) . Other acyl-carnitines, including acetyl-carnitine, could not be detected in this study. The serum level of pivalic acid increased with the duration of treatment, and decreased together with urinary pivaloylcarnitine excretion (Fig. 1D) . The levels of blood ammonia changed within the normal range (3O-8O 1c g/ 100 ml) except for one volunteer. In each volunteer, concentrations of pyruvate, lactate, ketone bodies and amino acids varied entirely within the normal range during the administration of CFTM-PI. However, a significant statistical correlation was observed between (r8=0.85, p<0.01, n=11). No significant correlation was found between levels of serum free carnitine and blood pyruvate, ketone bodies, or other amino acids (Fig. 3) .
In two volunteers receiving a placebo, neither a significant correlation between serum free carnitine and blood ammonia (rs = -0.33, n = 22) nor remarkable change of other parameters was observed.
Diseased children
No side effects relevant to CFTM-PI administration were observed throughout this study. On examination of the 7 patients who were drawn serially, there was a significant difference in the serum free carnitine levels before and during CFTM-PI administration (p <0.05), and a significant difference in serum free Fig 
Correlation analysis in diseased children during CFTM-PI administration
between levels of serum free carnitine and blood ammonia (A), pyruvate (B), lactate (C), plasma alanine (D), glutamic acid (E) or glutamine (F).
carnitine, blood ammonia and glutamic acid concentrations during and after the therapy (p <0.05). There were no significant differences in the levels of pyruvate, lactate and amino acids before, during and after administration of CFTM-PI, as shown in Fig. 4 . On correlation analysis during the administration, a negative correlation was revealed between the levels of free carnitine and blood ammonia (rs = -0.60, p < 0.05, n =16), and a significant correlation was also found between serum free carnitine and blood glutamine levels (rS =0.41, p <0.02, n=15), just as in the adult cases (Fig. 5) .
No significant correlation was found between levels of serum free carnitine and blood ammonia (rS = 0.11, n = 20) or glutamine (r8 = 0.17, n = 20) in the samples without CFTM-PI.
DISCUSSION
Drug-induced carnitine deficiency has been reported in patients receiving valproic acid (VPA) (Ohtani et al. 1982; Murphy et al. 1985) , sodium benzoate (Sakuma et al. 1989 ) and a mixture of sulfadiazine and pyrimethamine (Sekas and Paul 1993) . VPA, in particular, is well known to be apt to cause hyperammonemia (Ohtani et al. 1982) , fatal hepatic damage (Le Bihan et al. 1980 ) and Reye-like syndrome (Gerber et al. 1979; Bohles et al. 1982) . Antibiotics esterified with the pivaloyloxymethyl group, such as pivampicillin and CFTM-PI, are also known to cause carnitine deficiency. Up to the present, no severe side effects of this type of antibiotics have been reported. Recently, however, Diep et al. (1993) described patients who had muscle symptoms of weakness, asthenia and pain caused by carnitine depletion following long-term treatment with pivampicillin and pivmecillinam for 6-24 months. A biopsied muscle taken from one of these patients showed type II atrophy and lipid accumulation. After cessation of the therapy, the symptoms slowly disappeared and re-examination of a muscle specimen showed normal findings.
In our study of adult volunteers, we showed the lowering effect of CFTM-PI on serum free carnitine levels (Fig. 1) . These antibiotics are generally used as a short-term treatment for acute infection, and hence the possible influence of acute depletion of carnitine should be clarified as well as chronic carnitine deficiency. In this study, rapid reduction of serum free carnitine level following the administration of CFTM-PI was found to be associated with a large amount of pivaloylcarnitine excretion. During the deficient state of carnitine, serum pivalic acid concentration increased gradually. This suggest that the medication might cause a shortage of available tissue carnitine for conjugating with pivaloyl-CoA, a derivative of pivalic acid, thus leading to a rise of pivalic acid concentration.
An elevated ammonia level of 120.0 pg/100 ml was temporarily observed in only one volunteer without clinical manifestation. The others were within the normal range of ammonia, lactate and pyruvate levels. However, there was a Acid-Containing Prodrug Treatment 51 significant inverse correlation between serum free carnitine levels and concentrations of blood ammonia, lactate or alanine. In children's cases, a significant inverse correlation was found only between levels of serum free carnitine and blood ammonia. We need further study to evaluate the influence on levels of lactate and alanine in diseased children. The maximum ammonia level of 187 /1g/100 ml with free carnitine of 10.1 nmol/ml was found in a three-year-old male having upper respiratory infection at the end of 12 days' administration (16.3 mg/ kg/day).
No signs of hyperammonemia, carnitine deficiency or metabolic disease had been observed in this patient or any others.
VPA is known to cause hyperammonemia accompanied by a carnitine deficient state (Ohtani et al. 1982; Murphy et al. 1985) . Our previous study showed significantly reduced serum free carnitine levels by administration of VPA at the physiological dose (Kanayama et al. 1985) . At the same time, the serum free carnitine level was inversely proportional to levels of lactate, pyruvate and alanine as well as blood ammonia. Since administered VPA is metabolized to its CoA derivatives, it may reduce intramitochondrial free CoA and acetyl-CoA levels, which may in turn adversely influence mitochondrial functions such as f3-oxidation (Ponchaut et al. 1992 ; Kossak et al. 1993 ) and ornithine cycle (Coude et al. 1981 (Coude et al. , 1983 ). This metabolic alteration is probably responsible for rising blood ammonia, lactate and pyruvate levels and for inhibition of mitochondrial ATP production.
From this point of view, the data mentioned above indicate that long-term treatment with ordinary doses of VPA may inhibit mitochondrial functions (Ohtani et al. 1982) . In our present study of short-term treatment with CFTM-PI, we found that blood ammonia elevations were associated with possible carnitine depletion in both adult and children's tissues.
We also found a significant positive correlation between levels of serum free carnitine and blood glutamine both in adult volunteers and children's studies. In a hyperammonemic state, an increased glutamine level has been observed (Brusilow and Horwich 1989) . In this connection, Ratnakumari et al.(1993) recently reported that serum, cerebral and liver glutamine levels decreased after high-dose benzoate administration with increased ammonia levels in congenital hyperammonemic model mice. The same authors have explained that this decrease of glutamine levels was induced by reduced ATP and acetyl-CoA levels caused by benzoate therapy. The decreased blood glutamine level observed in our study might support the hypothesis that ordinary short-term treatment with CFTM-PI induces ATP and acetyl-CoA insufficiency because of carnitine deficiency, CoA sequestration or a combination of both. Kay et al.(1986) and Hjelm et al. (1986) have reported cases in which occult metabolic disorders were revealed during the administration of VPA. In other studies, L-carnitine supplementation was tried for normalization of carnitine deficiency in VPA-treated patients (Ohtani et al. 1982; Sakemi et al. 1992 ).
The medication of pivalic acid-containing antibiotics may have a possibility of adverse effect on mitochondrial functions even in short-term therapy, and hence, carnitine supplementation might be effective (Ohtani et al. 1982; Matsuda et al. 1987 ) for patients on these antibiotics especially those vulnerable to carnitine deficiency and/or hyperammonemia, such as organic acidemias, urea cycle disorders, fatty acid oxidation defects, recurrent Reye-like syndrome and receiving VPA or benzoate.
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